{"id":54717,"date":"2026-01-19T23:24:12","date_gmt":"2026-01-19T15:24:12","guid":{"rendered":"https:\/\/flcube.com\/?p=54717"},"modified":"2026-01-19T23:24:13","modified_gmt":"2026-01-19T15:24:13","slug":"akesos-gumokimab-nmpa-filing-for-ankylosing-spondylitis-expands-il-17a-franchise","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54717","title":{"rendered":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise"},"content":{"rendered":"\n<p><strong>Akeso Biopharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>) announced that the <strong>Center for Drug Evaluation (CDE) of NMPA<\/strong> has accepted a market filing for <strong>gumokimab (AK111)<\/strong>, an <strong>interleukin\u201117A (IL\u201117A) monoclonal antibody<\/strong>, for the treatment of <strong>active ankylosing spondylitis<\/strong>. The drug is already under NMPA review for <strong>psoriasis<\/strong>, positioning Akeso to capture a broader share of the <strong>autoimmune disease market<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Akeso Biopharma (9926.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Gumokimab (AK111)<\/td><\/tr><tr><td>**Mechanism<\/td><td>IL\u201117A monoclonal antibody<\/td><\/tr><tr><td>**Application<\/td><td>Market filing accepted<\/td><\/tr><tr><td>**Agency<\/td><td>CDE of NMPA (China)<\/td><\/tr><tr><td>**Indication<\/td><td>Active ankylosing spondylitis<\/td><\/tr><tr><td>**Status<\/td><td>Also under review for psoriasis<\/td><\/tr><tr><td>**Filing Date<\/td><td>14\u202fJan\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<p><strong>Role of IL\u201117:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pro\u2011inflammatory cytokine<\/strong> secreted by activated Th17 cells<\/li>\n\n\n\n<li><strong>Key pathogenic driver<\/strong> in psoriasis and ankylosing spondylitis via IL\u201117\/IL\u201117R signaling<\/li>\n\n\n\n<li>Mediates <strong>immune\u2011inflammatory responses<\/strong> leading to joint damage and skin lesions<\/li>\n<\/ul>\n\n\n\n<p><strong>Gumokimab Mechanism:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Specifically binds to IL\u201117A<\/strong>, blocking the IL\u201117\/IL\u201117R signaling pathway<\/li>\n\n\n\n<li><strong>Inhibits onset and progression<\/strong> of immune\u2011inflammatory responses<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Designed for <strong>high affinity and long half\u2011life<\/strong>, potentially offering <strong>improved dosing convenience<\/strong> vs. approved competitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Ankylosing Spondylitis Patients<\/strong><\/td><td>3.5\u202fmillion<\/td><td>20\u202fmillion<\/td><\/tr><tr><td><strong>Active Disease Requiring Biologics<\/strong><\/td><td>1.2\u202fmillion<\/td><td>7\u202fmillion<\/td><\/tr><tr><td><strong>IL\u201117 Inhibitor Penetration<\/strong><\/td><td>18\u202f%<\/td><td>35\u202f%<\/td><\/tr><tr><td><strong>Annual Cost (USD)<\/strong><\/td><td>$12,000\u201115,000<\/td><td>$35,000\u201150,000<\/td><\/tr><tr><td><strong>Market Value (2030E)<\/strong><\/td><td>$2.8\u202fbillion<\/td><td>$12.5\u202fbillion<\/td><\/tr><tr><td><strong>Gumokimab Peak Share<\/strong><\/td><td>8\u202f%<\/td><td>3\u202f%<\/td><\/tr><tr><td><strong>Peak Revenue (2032E)<\/strong><\/td><td>\u00a51.6\u202fbillion<\/td><td>$380\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Key Competitors:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cosentyx<\/strong> (secukinumab, Novartis) \u2013 first\u2011to\u2011market IL\u201117A inhibitor<\/li>\n\n\n\n<li><strong>Taltz<\/strong> (ixekizumab, Eli Lilly) \u2013 high efficacy, approved for AS<\/li>\n\n\n\n<li><strong>Siliq<\/strong> (brodalumab, Bausch) \u2013 IL\u201117RA blocker, niche use<\/li>\n\n\n\n<li><strong>Gumokimab<\/strong> \u2013 <strong>first domestic IL\u201117A inhibitor<\/strong> in China with <strong>potential biosimilar pricing advantage<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Indication Strategy:<\/strong> Filing for <strong>both psoriasis and ankylosing spondylitis<\/strong> maximizes market reach across <strong>\u00a58\u202fbillion combined autoimmune market<\/strong> in China<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Akeso\u2019s <strong>Guangzhou biologics facility<\/strong> (capacity 20,000\u202fL) can support both indications; <strong>GMP certification<\/strong> achieved 2025<\/li>\n\n\n\n<li><strong>Commercial Readiness:<\/strong> 800\u2011person autoimmune sales force established for psoriasis launch; <strong>ankylosing spondylitis expansion<\/strong> requires minimal additional investment<\/li>\n\n\n\n<li><strong>Next Milestone:<\/strong> <strong>NDA submission<\/strong> for psoriasis expected <strong>Q3\u202f2026<\/strong>; <strong>ankylosing spondylitis NDA<\/strong> planned for <strong>Q2\u202f2027<\/strong> following Phase\u202fIII completion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory approvals, and commercial forecasts for gumokimab. Actual results may differ due to competitive responses, pricing pressures, and market access dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[360,65,850,38],"class_list":["post-54717","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-akeso-biopharma","tag-auto-immune","tag-hkg-9926","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54717\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise\" \/>\n<meta property=\"og:description\" content=\"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54717\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T15:24:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T15:24:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise\",\"datePublished\":\"2026-01-19T15:24:12+00:00\",\"dateModified\":\"2026-01-19T15:24:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717\"},\"wordCount\":375,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Akeso Biopharma\",\"Auto-immune\",\"HKG: 9926\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54717#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54717\",\"name\":\"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-19T15:24:12+00:00\",\"dateModified\":\"2026-01-19T15:24:13+00:00\",\"description\":\"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54717\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54717#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise - Insight, China&#039;s Pharmaceutical Industry","description":"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54717","og_locale":"en_US","og_type":"article","og_title":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise","og_description":"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.","og_url":"https:\/\/flcube.com\/?p=54717","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-19T15:24:12+00:00","article_modified_time":"2026-01-19T15:24:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54717#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54717"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise","datePublished":"2026-01-19T15:24:12+00:00","dateModified":"2026-01-19T15:24:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54717"},"wordCount":375,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Akeso Biopharma","Auto-immune","HKG: 9926","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54717#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54717","url":"https:\/\/flcube.com\/?p=54717","name":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-19T15:24:12+00:00","dateModified":"2026-01-19T15:24:13+00:00","description":"Akeso Biopharma (HKG: 9926) announced that the Center for Drug Evaluation (CDE) of NMPA has accepted a market filing for gumokimab (AK111), an interleukin\u201117A (IL\u201117A) monoclonal antibody, for the treatment of active ankylosing spondylitis. The drug is already under NMPA review for psoriasis, positioning Akeso to capture a broader share of the autoimmune disease market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54717#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54717"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54717#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso\u2019s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL\u201117A Franchise"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54717"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54717\/revisions"}],"predecessor-version":[{"id":54727,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54717\/revisions\/54727"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}